Get the Stockscreener App
5.65
2.36%
0.13
After Hours:
5.71
0.06
+1.06%
Unicycive Therapeutics Inc stock is traded at $5.65, with a volume of 264.83K.
It is up +2.36% in the last 24 hours and down -9.31% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$5.52
Open:
$5.56
24h Volume:
264.83K
Relative Volume:
0.65
Market Cap:
$121.43M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-3.6452
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
+1.07%
1M Performance:
-9.31%
6M Performance:
+22.83%
1Y Performance:
+643.91%
1-Day Range:
$5.425
$5.65
1-Week Range:
$5.36
$5.95
52-Week Range:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.65 | 118.63M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - marketscreener.com
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - marketscreener.com
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum ... - Caledonian Record
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - marketscreener.com
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Yahoo Finance
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rally Mode: Can Unicycive Therapeutics Inc stock continue upward trendJuly 2025 Outlook & Fast Moving Stock Trade Plans - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Why Unicycive Therapeutics Inc. stock is a must watch in 2025Trade Risk Summary & Verified Stock Trade Ideas - Улправда
Is Unicycive Therapeutics Inc. stock a top momentum playLong Setup & Smart Investment Allocation Insights - Улправда
Will Unicycive Therapeutics Inc. stock remain a Wall Street favorite2025 Biggest Moves & Long-Term Growth Stock Strategies - Bollywood Helpline
How Unicycive Therapeutics Inc. stock performs after earningsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
How Unicycive Therapeutics Inc. stock benefits from tech adoptionLong Setup & Daily Technical Forecast Reports - Улправда
Will Unicycive Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Summary & Long-Term Growth Plans - Bölüm Sonu Canavarı
Can Unicycive Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Weekly Recap & Consistent Profit Alerts - Улправда
Why analysts upgrade Unicycive Therapeutics Inc. stockEarnings Performance Report & Fast Exit Strategy with Risk Control - DonanımHaber
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025Portfolio Performance Report & Accurate Entry and Exit Point Alerts - DonanımHaber
Can Unicycive Therapeutics Inc. stock continue upward trend2025 Stock Rankings & Daily Profit Focused Stock Screening - DonanımHaber
How interest rate cuts could boost Unicycive Therapeutics Inc. stockWeekly Investment Report & Free Fast Gain Swing Trade Alerts - DonanımHaber
How geopolitical tensions affect Unicycive Therapeutics Inc. stockJuly 2025 Fed Impact & High Accuracy Swing Trade Signals - ulpravda.ru
Aug Summary: Why Unicycive Therapeutics Inc. stock is a must watch in 20252025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chart Watch: Why analysts upgrade Unicycive Therapeutics Inc stock2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Unicycive is all-in on kidney care, focusing on underserved areas: CEO - AlphaStreet
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6%Time to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Important Notice to Long-Term Shareholders of Five Below, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):